Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CNTO 2476 · 1 trial · 1 indication
This number will be summarized descriptively for treated and fellow eyes within each dose level included in Phase 1 and Phase 2a portions of the study
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | Phase 1: 3 patients will receive 60,000 human umbilical tissue-derived cells (hUTC) |
| Cohort B | EXPERIMENTAL | Phase 1: 3 patients will receive 120,000 hUTC |
| Cohort C | EXPERIMENTAL | Phase 1: 3 patients will receive 300,000 hUTC |
| Cohort D | EXPERIMENTAL | Phase 1: 3 patients will receive 560,000 hUTC |
| Cohort E | EXPERIMENTAL | Phase 1: 6 patients will receive 300,000 hUTC |
| Cohort F | EXPERIMENTAL | Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC |
| Cohort G | EXPERIMENTAL | Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC |
| Phase 2a | EXPERIMENTAL | Up to 38 patients will receive one of two optimal doses as selected from the Phase 1 portion of the study |
| Name | Type | Description |
|---|---|---|
| CNTO 2476 | BIOLOGICAL | - |
| iTrack Model 275 micro catheter | PROCEDURE | CNTO 2476 will be administered subretinally using the iTRACK microcatheter in participants with visual acuity impairment. During surgery, the portion of microcatheter distal to the flexible blue hub is inserted into the subretinal space via a peripheral scleral cutdown and choroidal fistula. |
Inclusion Criteria: * Women must be incapable of childbearing * Patient must be a suitable candidate for ophthalmologic surgery, is willing and able to comply with the surgical procedure, scheduled visits, treatment plan, laboratory tests and other study procedures * Confirmed diagnosis of bilatera...
CNTO 2476 is an investigational monoclonal antibody being studied for the treatment of age-related macular degeneration, a condition that affects the central part of the retina and can lead to vision loss. It is currently in clinical development for this ophthalmologic indication.
CNTO 2476 is a monoclonal antibody, but its specific molecular target has not been disclosed in available clinical trial information. The drug is being investigated for its potential role in treating age-related macular degeneration, though the exact mechanism of action is not publicly detailed.
CNTO 2476 is being developed by Johnson & Johnson, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug.
CNTO 2476 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical evaluation for age-related macular degeneration.
CNTO 2476 has been studied in one clinical trial, identified as NCT01226628, titled "A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration." This Phase 1 study was completed and enrolled 39 participants in the United States.
CNTO 2476 is an investigational drug and no alternative names have been reported in clinical trial records. It is distinct from other approved therapies for age-related macular degeneration, and its development is being conducted under this specific compound identifier.